胚胎活检与冻融单胚胎移植后母婴结局的关联
本研究基于2014至2017年马萨诸塞州辅助生殖技术监测数据,比较冻融单胚胎移植后胚胎活检组(n=585)与无活检组(n=2191)的母婴结局。结果显示,活检组子痫前期、妊娠期高血压、胎盘疾病、早产、低出生体重、剖宫产、妊娠期糖尿病及母婴住院时间延长风险均未显著增加。
要点
- 胚胎活检未显著增加子痫前期、妊娠期高血压及胎盘疾病风险。
- 活检组早产、低出生体重、剖宫产及妊娠期糖尿病风险无显著差异。
- 母婴住院时间延长在两组间也无显著差异。
核心结论
- 胚胎活检用于植入前遗传学检测不增加胎盘形成相关诊断、母体疾病或母婴住院时间延长的风险。
研究设计与样本
- 研究链接了2014至2017年马萨诸塞州辅助生殖技术监测数据与出生证明及住院出院诊断,仅纳入冻融单胚胎移植后的单胎分娩。
- 比较活检组(n=585)与无活检组(n=2191),使用卡方检验和逻辑回归调整母亲年龄、种族、教育、产次、体重指数、出生年份、保险及所有不孕诊断。
主要发现
- 子痫前期调整OR 0.82(95%CI 0.42-1.61;P=.5685),妊娠期高血压调整OR 0.85(95%CI 0.46-1.59;P=.6146)。
- 胎盘疾病(包括胎盘早剥、前置胎盘、植入性胎盘谱系)调整OR 1.16(95%CI 0.60-2.24;P=.6675)。
- 早产调整OR 1.22(95%CI 0.73-2.03;P=.4418),低出生体重调整OR 1.12(95%CI 0.58-2.15;P=.7355)。
- 剖宫产调整OR 1.04(95%CI 0.79-1.38;P=.7762),妊娠期糖尿病调整OR 0.83(95%CI 0.50-1.38;P=.4734)。
- 母亲住院时间延长调整OR 1.23(95%CI 0.83-1.80;P=.3014),婴儿住院时间延长调整OR 1.29(95%CI 0.72-2.29;P=.3923)。
临床怎么用
- 对于计划进行胚胎活检及冻融单胚胎移植的患者,可告知活检未显著增加所研究的母婴不良结局风险。
- 临床决策中,胚胎活检的潜在获益无需因担忧上述产科或新生儿结局而受阻。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Contemporary embryo biopsy in the United States involves the removal of several cells from a blastocyst that would become the placenta for preimplantation genetic testing. Embryos are then cryopreserved while patients await biopsy results, with transfers occurring in a subsequent cycle as a single frozen-thawed embryo transfer, if euploid. OBJECTIVE: We sought to determine if removal of these cells for preimplantation genetic testing was associated with adverse obstetrical or neonatal outcomes after frozen-thawed single embryo transfer. STUDY DESIGN: We linked assisted reproductive technology surveillance data from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System to birth certificates and maternal and neonatal hospitalization discharge diagnoses in Massachusetts from 2014 to 2017, considering only singleton births after frozen-thawed single embryo transfers. We compared outcomes of cycles having embryo biopsy (n=585) to those having no biopsy (n=2191) using chi-square for categorical and binary variables and logistic regression for adjusted odds ratios and 95% confidence intervals, adjusting for mother's age, race, education, parity, body mass index, birth year, insurance, and all infertility diagnoses. RESULTS: Considering no biopsy as the reference, there was no difference between groups with respect to preeclampsia (adjusted odds ratio, 0.82; 95% confidence interval, 0.42-1.61; P=.5685); pregnancy-induced hypertension (adjusted odds ratio, 0.85; 95% confidence interval, 0.46-1.59; P=.6146); placental disorders, including placental abruption, placenta previa, placenta accreta, placenta increta, and placenta percreta (adjusted odds ratio, 1.16; 95% confidence interval, 0.60-2.24; P=.6675); preterm birth (adjusted odds ratio, 1.22; 95% confidence interval 0.73-2.03; P=.4418); low birthweight (adjusted odds ratio, 1.12; 95% confidence interval, 0.58-2.15; P=.7355); cesarean delivery (adjusted odds ratio, 1.04; 95% confidence interval, 0.79-1.38; P=.7762); or gestational diabetes mellitus (adjusted odds ratio, 0.83; 95% confidence interval, 0.50-1.38; P=.4734). In addition, there was no difference between the groups for prolonged hospital stay for mothers (adjusted odds ratio, 1.23; 95% confidence interval, 0.83-1.80; P=.3014) or for infants (95% confidence interval, 1.29; 95% confidence interval, 0.72-2.29; P=.3923). CONCLUSION: Embryo biopsy for preimplantation genetic testing does not increase the odds for diagnoses related to placentation (preeclampsia, pregnancy-related hypertension, placental disorders, preterm delivery, or low birthweight), maternal conditions (gestational diabetes mellitus), or maternal or infant length of stay after delivery.
引用
- Sites CK, Bachilova S, Gopal D, et al. Embryo biopsy and maternal and neonatal outcomes following cryopreserved-thawed single embryo transfer. Am J Obstet Gynecol. 2021. PMID: 33894152. doi:10.1016/j.ajog.2021.04.235
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。